Immunome, Inc. (IMNM) vs uniQure N.V. (QURE)
Immunome, Inc. and uniQure N.V. are both Biotechnology companies. Immunome, Inc. and uniQure N.V. are of similar size ($2.7B and $2.6B). uniQure N.V. grew revenue faster over the last twelve months: 30.2% against 16.7%. Immunome, Inc. has the higher net margin (0.00% vs −1,350.7%) and the lower return on invested capital (−3,323.0% vs 0.00%). Across the 17 metrics below, Immunome, Inc. leads on 10 and uniQure N.V. on 7.
Valuation
Profitability
| Metric | IMNM | QURE | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 92.49% | 65.16% |
| Operating margin | 0.00% | (1,071.53%) | 0.00% |
| Net margin | 0.00% | (1,350.73%) | 0.00% |
| Free cash flow margin | 0.00% | (864.67%) | 0.00% |
| Return on equity | (64.03%) | (157.61%) | (57.72%) |
| Return on assets | (59.03%) | (32.13%) | (49.22%) |
| Return on invested capital | (3,322.99%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack